Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tempest Therapeutics ( (TPST) ) has shared an announcement.
On February 25, 2026, Tempest Therapeutics reported interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, an autologous CD19/BCMA dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma, alongside results from a prior investigator-initiated trial. As of late January 2026, all six efficacy-evaluable REDEEM-1 patients achieved complete responses, the combined overall response rate across both studies was 100% in 25 evaluable patients, safety was favorable with no Grade 3 or higher CRS or ICANS, and prior data showed a median progression-free survival of 23.1 months, prompting Tempest to accelerate TPST-2003’s development, present expanded data later in 2026, and prepare for a potential U.S. registrational study while also positioning its parallel dual-targeting CAR platform for broader oncology and immunology indications.
The most recent analyst rating on (TPST) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and significant cash burn with a shrinking equity cushion). Technicals remain soft with price below key longer-term averages and negative MACD. Corporate events are mixed (Nasdaq compliance risk vs. governance approvals), and valuation metrics offer limited support due to negative earnings and no dividend.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing advanced cell therapies and small molecule product candidates to treat cancer. Its lead efforts include a pipeline of CAR-T therapies, notably TPST-2003, targeting relapsed/refractory multiple myeloma and potentially other hematologic and immune-related diseases, with development activities spanning China and planned expansion into the U.S.
Average Trading Volume: 109,727
Technical Sentiment Signal: Sell
Current Market Cap: $33.57M
Learn more about TPST stock on TipRanks’ Stock Analysis page.